文献速递血栓与止血

白细胞介素-33受体(ST2)是减轻血友病性关节病进展的新治疗靶点

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.
PubMed 文献 · Blood · 2025-01-01

研究利用CRISPR/Cas9靶向F8基因外显子1构建的重度血友病A小鼠模型(F8em1-/-),发现关节损伤后滑膜中IL-1家族细胞因子IL-1β和IL-33及其受体表达上调,血浆可溶性ST2和IL-33在急性期升高;ST2缺陷的血友病小鼠关节损伤显著减轻,阻断ST2可改善关节损伤,提示ST2是血友病性关节病的潜在治疗靶点。

要点

  • F8em1-/-小鼠自发性出血外显率高,关节出血进展为关节病。
  • 针刺诱导关节损伤后滑膜IL-1β、IL-33及受体IL-1RAcP、ST2表达上调。
  • ST2缺陷或阻断ST2可显著减轻血友病小鼠关节损伤。

核心结论

  • 在新型血友病性关节病小鼠模型中,ST2在发病机制中起关键作用,并可能是新的治疗靶点。

研究设计与样本

  • 研究使用CRISPR/Cas9靶向F8基因外显子1构建的重度血友病A小鼠模型(F8em1-/-),并进行针刺诱导膝关节损伤。

主要发现

  • F8em1-/-小鼠自发性出血外显率高,关节出血进展为关节病。
  • 损伤关节滑膜中IL-1β、IL-33及受体IL-1受体辅助蛋白和T1/ST2(ST2)表达上调。
  • F8em1-/-小鼠关节针刺损伤急性期血浆可溶性ST2和IL-33水平升高。
  • ST2缺陷的血友病小鼠(双基因敲除)针刺损伤后关节损伤较F8em1-/-小鼠显著减轻。
  • 治疗性阻断ST2可显著改善血友病小鼠血友病性关节病期间的关节损伤。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A is an X-linked bleeding disorder caused by a blood clotting protein factor VIII deficiency. Patients with hemophilia develop recurrent bleeding episodes. When bleeding occurs in the joints, hemophilic arthropathy (HA) may develop, resulting in hemarthroses and joint deformation. A novel congenic mouse model of severe hemophilia A was generated using CRISPR/CRISPR-associated protein 9 targeting of exon 1 of the F8 gene (F8em1-/-) to explore changes in the bleeding and inflammation during HA. F8em1-/- mice have a high penetrance of spontaneous bleeding, with joint bleeds progressing to arthropathy. F8em1-/- mice were subjected to needle-induced damage to the knee to assess synchronized joint bleeding, and the development of HA and synovial inflammation was assessed. The synovium of injured joints of F8em1-/- mice had differential and temporal expression of inflammatory genes after injury. Pathway analysis identified upregulation of the interleukin-1 (IL-1) family cytokines, IL-1β and IL-33; and respective receptors IL-1 receptor accessory protein and T1/ST2 (ST2) in the synovium of mice after needle-induced HA. Soluble ST2 and IL-33 levels were elevated in the plasma of F8em1-/- mice in acute stages after needle injury to the joints. Dual ST2-deficient F8em1-/- mice were generated, with ST2-deficient hemophilic mice developing significantly reduced joint damage after needle injury relative to F8em1-/- mice. Using a therapeutic intervention, blocking ST2 after joint injury significantly ameliorated joint damage during HA in hemophilic mice. These studies in a new mouse model of HA identify a crucial role of ST2 in HA pathogenesis and highlight its potential as a novel therapeutic target.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hawerkamp HC, Yeow A, Byrne CM, et al. The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy. Blood. 2025. PMID: 40680269. doi:10.1182/blood.2024027578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。